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ABSTRACT
Background: Neutropenia is a major risk factor for infection. The prevalence of 
Gram-negative bacteria decreased in the early nineties, while the frequency 
of Gram-positive bacteria increased from between 55 to 70% of all bacteremia 
episodes. Even more recently there has been a resurgence of Gram-negative 
infections. The aim of this report is to describe the microbiological findings in a 
cohort of febrile neutropenic patients in a tertiary teaching hospital of Southern 
Brazil. 
Methods: This was a cohort study designed to evaluate the implementation of 
a clinical protocol for treatment of febrile neutropenic patients. Prospectively 
included in our study were patients with febrile neutropenia (FN) admitted between 
January 2004 and December 2005 at the Hospital de Clínicas of Porto Alegre. 
Historical controls were selected from patient visits recorded between March 2001 
and April 2003 - or recorded before the clinical protocol was introduced. 
Results: During the 2004-2005 and 2001-2003 study periods, 164 and 159 
pathogens were documented, respectively. In 93 of 190 episodes (48.9%), and 84 
of 193 episodes (43.5%) there were documented microbiological infections. Fungal 
infection was documented in very few episodes (6.1 vs. 5.7%). We also observed 
a 52.8% prevalence of Gram-positive and a 47.2% prevalence of Gram-negative 
bacteria in the 2001-2003 period. Observed in the 2004-2005 period were 38.1% 
Gram-positive and 61.9% Gram-negative bacteria (P=0.012). There was also a 
significant increase in Pseudomonas aeruginosa prevalence in the second study 
period (1.9 to 11.6%; P<0.001). Six isolates (31.6%) were discovered to be multi-
resistant in the 2004-2005 period versus none in the first period. The prevalence 
of Oxacillin-resistant Staphylococcus was 53.5 and 65.8% in the first and second 
periods, respectively (P=0.23).
Conclusion: These documented pathogens are the most commonly observed 
in febrile neutropenic patients, but the emergence of multidrug-resistant 
Pseudomonas aeruginosa is of some concern.
Keywords: Neutropenia fever; microbiology; drug resistance; bacterial; 
Pseudomonas; Staphylococcus; epidemiology
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Approximately 10 to 50% of patients with solid 
tumors, and more than 80% of these with hematologic 
malignancies, will develop febrile neutropenia (FN) 
after chemotherapy (1). The mortality rate associated 
with FN is decreasing but is still a concern (1-4). The 
prevalence of Gram-negative bacteria (Escherichia 
coli, Pseudomonas aeruginosa, and Klebsiella spp), 
represented 60 to 70% of all documented infections in 
the seventies and eighties but decreased in the early 
1990’s. At the same time, frequency of Gram-positive 
bacteria (Staphylococcus aureus, Streptococcus 
viridans and Streptococcus pneumoniae) increased to 
a level of between 55 - 70% of all bacteremia episodes 
(5). This change may be attributed to prophylaxis with 
fluoroquinolones, the toxicity associated with more 
intensive chemotherapy and the higher usage rates 
of intravenous catheters (6). On the other hand, other 
studies have shown that there has been resurgence 
of Gram-negative infections (7,8). Non-bacterial 
infections are caused mostly by fungi. Thus, more than 
20% of all neutropenic patients may develop systemic 
fungal infections - 90% of which consist of the Candida 
spp., Aspergillus spp., Fusarium spp., or Scedosporium 
spp. (5).
The rates of documented microbiological infections are 
between one-third to one-half of all febrile neutropenic 
episodes (8,9), and the majority of microbiologically 
infected patients need empirical broad-spectrum 
antibiotic therapy for fevers of unknown origins. Currently, 
much attention is being paid to resistance issues, and 
resistant strains are now considered a serious public 
health concern. Thus, special care concerning specific 
pathogens is needed including: methicillin-resistant 
Staphylococcus aureus (MRSA), coagulase-negative 
staphylococci, vancomycin-resistant enterococci, viridans 
group streptococci, ciprofloxacin-resistant Escherichia 
coli, and Pseudomonas aeruginosa (10). Considering 
the importance of local characteristics in the pattern 
of microorganisms causing infections, it is important to 
know their epidemiology. Institutional clinical guidelines 
are developed to aid in the choice of the most effective 
treatment based on the local pathogenic profile and the 
epidemiologic pattern of resistance (4,11). Adherence to 
proposed recommendations seems to be associated with 
RESUMO
Introdução: Neutropenia é um forte fator de risco para infecção. A prevalência de bactérias Gram-
negativas diminuiu no início da década de 90 e a frequência de bactérias Gram-positivas aumentou 
em 55 a 70% em todos os episódios de bacteremia. Porém, mais recentemente, infecções por bactéria 
Gram-negativas ressurgiram. O objetivo deste estudo é descrever os achados microbiológicos em 
uma coorte de pacientes neutropênicos febris em um hospital terciário de ensino do sul do Brasil.
Metodologia: Estudo coorte para avaliação da implementação de um protocolo clínico para o 
tratamento de pacientes neutropênicos febris. Foram incluídos prospectivamente pacientes com 
neutropenia febril (NF) admitidos entre janeiro de 2004 e dezembro de 2005 no Hospital de Clínicas 
de Porto Alegre. Controles históricos foram selecionados de visitas de pacientes entre março de 
2001 e abril de 2003 ou antes do protocolo clínico ter sido implementado.
Resultados: Nos períodos do estudo de 2004-2005 e 2001-2003, foram documentados 164 e 159 
patógenos, respectivamente. Em 93 de 190 episódios (48,9%) e 84 de 193 episódios (43,5%) foram 
documentadas infecções microbiológicas. Infecções fúngicas foram documentadas em poucos 
episódios (6,1 e 5,7%). Observou-se uma prevalência de 52,8% de bactérias Gram-positivas e 
47,2% de bactérias Gram-negativas no período de 2001-2003. No período de 2004-2005, foram 
observadas 38,1% de bactérias Gram-positivas e 61,9% de bactérias Gram-negativas (P=0,012). 
Também houve um aumento significativo da prevalência de Pseudomonas aeruginosa no segundo 
período de estudo (1,9 para 11,6%; P<0,001). Em 2004-2005, seis isolados eram multirresistentes 
(31,6%). A prevalência de Staphylococcus resistente à oxacilina foi de 53,5 e 65,8% nos primeiros e 
segundos períodos, respectivamente (P=0,23).
Conclusão: Os patógenos documentados neste estudo são os mais comuns em pacientes 
neutropênicos febris, mas a emergência de Pseudomonas aeruginosa resistente a multidrogas é 
uma preocupação.
Palavras-chave: Neutropenia; febre; microbiologia; resistência a medicamentos; bacteriano; 
Pseudomonas; Staphylococcus; epidemiologia
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better clinical outcomes (3). In view of the importance 
of such pathogenic profiles, then, it is our purpose to 
describe the microbiological findings in a cohort study 
of febrile neutropenic patients in a tertiary teaching 
hospital of Southern Brazil. Further, our study is designed 
to evaluate the clinical protocol for implementing 
treatment of such neutropenic patients (3).
METHODS
Patients hospitalized from January 2004 to December 
2005, and who presented with febrile neutropenia at 
the Hospital de Clínicas of Porto Alegre (HCPA), were 
prospectively included in our study. Historical controls 
were selected from the records including those from 
March 2001 to April 2003 - a period before the clinical 
protocol was introduced. HCPA is a general and public, 
tertiary teaching hospital in Southern Brazil with 742 
beds. The Hematology Unit admits neutropenic patients 
who are then submitted to high-dose chemotherapy 
and/or hematopoietic stem cell transplants (HSCT). 
Our study was approved by the institution’s Review and 
Ethics Committee.
Patients with a granulocyte count up to 1,000/
mm³ or neutrophils up to 500/mm³ were identified 
by the hospital’s computerized system and had their 
registration records revised so as to be included in the 
study. These identified neutropenic febrile patients 
were then followed until either hospital discharge or 
death. Only the first episode of febrile neutropenia in 
each hospitalization was considered. Exclusion criteria 
included: patients who were less than 18 years old, 
those who were HIV positive, and patients with their 
neutropenic episode secondary to infection.
Before antimicrobial therapy was initiated, culture 
specimens were obtained routinely according to the 
suspected focus of infection. Beyond merely blood tests, 
the origin of these cultures might include peripheral blood 
in the catheter, urine, and sputum, among other sources. 
All isolated culture specimens were identified at the 
microbiological laboratory of HCPA by routine methods. 
Species identification was confirmed with standard 
reference methods, and susceptibility testing was 
performed through disk diffusion method (Kirby Bauer).
A sample size of 200 episodes per period was 
calculated for the primary objective of the study, not 
included in this paper. Data were analyzed with the 
Statistical Package for the Social Sciences 13.0 (SPSS 
Inc.), Chicago, IL, USA, and a level of significance of 
0.05 was considered for our study. Chi-square statistics 
were used in the comparison of categorical variables, 
and Student’s t-test was applied to compare continuous 
variables. 
RESULTS
We identified 630 patients from the computerized 
hospital system for the 2001-2003 period and 530 
patients for the 2004-2005 period. One hundred 
ninety three in the first and 190 in the second period 
met the inclusion criteria. The characteristics of the 
studied sample are shown in Table 1.
Patients included after the clinical protocol 
implementation in the 2004-2005 period were 
younger than those from the 2001-2003 control 
period. There were also more patients after the 
protocol implementation with multiple myeloma and 
fewer patients with diseases other than leukemia, 
lymphoma, solid tumors, and other hematological 
diseases. Finally, there were more skin and intravenous 
catheter infections from the 2004-2005 period.
In the 2004-2005 study period 691 blood cultures 
were performed, while there were 740 for the 2001-
2003 period. Respectively, there were 164 (23.7%) 
and 159 (21.0%) pathogens documented. There were 
microbiological infections documented in 93 of 190 
episodes (48.9%) from the first period and 84 of 
193 episodes (43.5%) from the second. Pathogens 
isolated from neutropenic patients are presented in 
Table 2. Fungal infection was also documented in a 
few episodes. The rate of non-fermentative Gram-
negative rods (18.3%) was documented in the 2004-
2005 period and was higher than the finding in the 
2001-2003 period (6.9%) (P=0.002). Computing only 
291 pathogens identified as Gram-positive or Gram-
negative bacteria, we observed a change from a 
predominance of Gram-positive bacteria before the 
clinical protocol implementation to that of the Gram-
negative bacteria following: 52.8% Gram-positive 
and 47.2% Gram-negative versus 38.1% and 61.9%, 
respectively (P=0.012). The rate of Gram-positive 
cocci clusters from the 2001-2003 period was 22.6% 
(N=159) and 33.3% (N=164) in the 2004-2005 period 
(P=0.031).
We found a significant increase in the prevalence 
of Pseudomonas aeruginosa in the 2004-2005 period 
(P<0.001). Among the three cases of Pseudomonas 
documented in 2001-2003, one was found to be 
amikacin resistant (33.3%) and non-multidrug-
resistant. The prevalence of resistance in the 2004-
2005 period was not statistically different (31.6%), 
but six isolates were multi-resistant (31.6%). The 
prevalence of Staphylococcus oxacillin-resistant was 
53.5% for the first period and 65.8% for the 2004-
2005 period (P=0.230).
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Table 1 - Sample characteristics before and after implementation of the protocol for  
treatment of febrile neutropenia. 
Characteristics
2004/2005
(n  = 190)
2001/2003
(n  = 193)
P - value*
Male – n (%) 100 (52.6) 116 (60.1) 0.170
Age - mean (DP) 44.9 (14.9) 49.0 (15.6) 0.009†
Underlying disease – n (%)
Leukemias 94 (49.5) 90 (46.6) 0.650
Lymphomas 38 (20.0) 40 (20.7) 0.961
Other hematological diseases 6 (3.2) 8 (4.1) 0.808
Solid tumors 21 (11.1) 30 (15.5) 0.253
Multiple Myeloma 30 (15.8) 17 (8.8) 0.054
Other diseases 1 (0.5) 8 (4.1) 0.045
Neutropenia Causes – n (%) 1.000
Acute disease 23 (12.1) 24 (12.4)
Chemotherapy 167 (87.9) 169 (87.6)
Infection site – n (%)
Pulmonary 21 (10.3) 22 (11.3) 0.751
Urinary Tract 23 (11.3) 16 (8.2) 0.303
Gynecological  0 (0.0) 1 (0.5) 0.489
Gastrointestinal Tract 9 (4.4) 3 (1.5) 0.952
Skin 11 (5.4) 3 (1.5) 0.037
Catheter 21 (10.3) 10 (5.1) 0.054
Superior Air Ways 8 (3.9) 5 (2.6) 0.446
Other 4 (2.0) 4 (2.1) 1.000
Unknown 107 (52.5) 131 (67.2) 0.003
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Table 2 - Pathogen distribution during the periods before and after implementation 
of the protocol for treatment of febrile neutropenia. 





P - value 
*
Non fermenting Gram-negative rods 11 (6.9) 30 (18.3) 0.002
Pseudomonas aeruginosa 3 (1.9) 19 (11.6)
Acinetobacter spp. 6 (3.8) 7  (4.3)
Stenotrophomonas spp. 2 (1.2) 4 (2.4)
Fermenting Gram-negative rods 42 (26.4) 52 (31.7) 0.295
Klebsiella pneumoniae 11 (6.9) 14 (8.5)
Escherichia coli 19 (11.9) 20 (12.2)
Proteus spp. 3 (1.9) 1 (0.6)
Salmonella spp. 0 1 (0.6)
Citrobacter spp. 0 1 (0.6)
Serratia spp. 2 (1.3) 1 (0.6)
Haemophilus spp. 2 (1.3) 2 (1.2)
Alcaligenes spp. 0 1 (0.6)
Enterobacter spp. 5 (3.1) 11 (6.7)
Other rods** 22 (13.8 ) 15 (9.1) 0.186
Gram-negative 15 ( 9.4) 9 (5.5)
Gram-positive 7 (4.4) 6 (3.6)
Gram-positive cocci clusters 53 (33.3) 37 (22.6) 0.031
S. aureus 25 (15.7) 18 (11)
S. coagulase negative 28 (17.6) 19 (11.6)
Gram-positive cocci chain 16 (10.1) 13 (7.9) 0.502
Streptococcus spp. (other than S. pneumoniae) 10 (6.3) 8 (4.9)
S. pneumoniae 0 1 (0.6)
Enterococcus species 6 (3.8) 4 (2.4)
Other cocci 6 (3.8) 7 (4.3) 0.821
Fungi 9 (5.7) 10 (6.1) 0.867
Pneumocistis jiroveci 2 (1.3) 2 (1.2)
Candida spp. 6 (3.8) 7 (4.3)
Aspergillus spp. 1  (0.6) 1 (0.6)
DISCUSSION
This paper describes the microbiological findings 
for patients with febrile neutropenic episodes 
conducted in a tertiary teaching hospital in Southern 
Brazil. A great number of culture specimens were 
obtained, and one half of the episodes were 
microbiologically documented. These results are 
among the best reported in other studies (8,12). A 
shift was recorded from Gram-positive bacteria to 
Gram-negative infections from the 2001-2003 period 
to the 2004-2005 period.
In both periods studied, only 6.0% of identified 
pathogens were fungi, and these findings were similar 
to those identified in a Brazilian multicenter study 
(7) as well as those reported in other countries (13). 
As we expected, Candida was the most frequently 
documented invasive fungal infection (7). Fungal 
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infections represent a major concern given the relatively 
insensitive diagnostic methods and the poor associated 
outcome. 
Several observational studies have demonstrated a 
shift from Gram-negative to Gram-positive organisms 
in documented microbiological infections with 
neutropenic patients (12) - findings such as those 
observed for the 2001-2003 period. But the shift 
back to Gram-negative predominance observed in 
2004–2005 seems also to be a change described by 
other authors (9,12,14). Higher rates of Gram negative 
infections were also observed among neutropenic 
cancer patients in HCPA during the 2006-2008 period 
(from personal communication). Bow et al. suggest 
a reason for this movement might be a decline in the 
use of fluoroquinolones (6). In the 2004-2005 period 
we recorded a lower use of fluoroquinolones (data not 
shown), and the observed change in microbiology was 
attributed mainly to the decrease in Staphylococcus 
aureus bacteria and Staphylococcus coagulase-negative, 
not including the increase in non-fermentative Gram-
negative bacilli (especially P. aeruginosa) (table 2). 
In 2011, according to the HCPA Infectious Control 
Committee, the prevalence of Gram-positive bacteria 
represented 58.6% of documented infections in 
neutropenic cancer patients from HCPA. This shift back 
to Gram-positive predominance was also described in 
others studies (15). These changes are important, for 
they guide the policy of antimicrobial prophylaxis as 
well as treatment of neutropenic cancer patients. 
The SENTRY Program (19) reported that the most 
significant resistance problems in Latin American 
countries are the multidrug resistant non-fermentative 
Gram-negative bacilli like P. aeruginosa and 
Acinetobacter species - pathogens that appear relatively 
frequently in our study. Klebsiella pneumoniae and E.coli 
are among the most frequently isolated Gram-negative 
organisms in our 2001-2003 sample, as they were in 
other settings (20). They persist as major pathogens, 
but P. aeruginosa emerged in 2004-2005 as one of the 
most common Gram-negative bacilli. 
Two of the most common pathogens isolated in 
Brazilian Hospitals between the years 2007 to 2010 
were Klebsiella spp and Acinetobacter spp (7). That 
condition does not seem to be restricted to neutropenic 
patients since the Mystic Program Brazil 2003 (21) 
recorded P. aeruginosa to be the leading Gram-negative 
bacilli among all isolates from twenty Brazilian centers. 
The prevalence of the resistant Pseudomonas species in 
the Mystic Program was 36.6% for amikacin and 36.0% 
for meropenem. The emergence of multidrug-resistant 
Gram-negative rods as frequently reported pathogens 
in neutropenic patients is of increasing concern. This 
trend is likely a consequence of antibiotic selection 
pressure resulting from the use of some antibiotics like 
carbapenems (22). 
As reported in other studies (23), among the 
Gram-positive microorganisms the foremost identified 
pathogens were S. aureus and Staphylococcus 
coagulase-negative. Gram-positive cocci clusters are 
chiefly linked with intravascular catheter infections - 
infections that were more frequently found in the 2004-
2005 period as compared to the 2001-2003 period. The 
incidence of oxacillin-resistant Staphylococcus was also 
higher during 2004-2005, although the difference is not 
statistically significant and may well be the result of the 
low statistical power (65%) of our study. The prevalence 
data of the HCPA Infectious Control Committee for 2001-
2005, on oxacillin-resistant S. aureus and Staphylococcus 
coagulase-negative were 58 and 71%, respectively, 
thereby indicating that the pattern of neutropenic 
patient infections followed nosocomial epidemiology. 
This finding is similar in two Brazilian teaching hospitals 
where oxacillin-resistant S. aureus was responsible for 
64.3% of hospital-acquired S. aureus cases of infection 
(24). In the SENTRY Antimicrobial Surveillance Program 
between 2005-2008, the Gram-positive organisms most 
frequently isolated were S.aureus (20%), Staphylococcus 
coagulase-negative (14,7%), and Enterococcus spp. 
Resistance to oxacillin was 31% for S. aureus, and 
vancomycin resistance significantly increased among 
enterococci (23). 
Antimicrobial resistance is associated with increases 
in mortality, morbidity, length of hospital stay, and 
cost of health care (25). Therefore, there is concern 
that the emergence of multidrug-resistant pathogens 
as frequent aggressors in neutropenic patients may 
contribute to the failure of empirical treatment. At one 
time, the institutional clinical protocol recommended 
cefepime, or cefepime combined with amikacin, as the 
initial empirical therapy. These regimens were effective 
against most bacteria documented in this study. In case 
of Staphyloccus oxacillin-resistant, vancomycin persists 
as the most available alternative, but antimicrobial 
resistance among P. aeruginosa may yet complicate the 
treatment thereby limiting therapeutic choices.
This study has limitations that must be taken into 
account. It was not sufficiently powered to compare the 
prevalence rates of pathogens, and it also had insufficient 
statistical power to detect small differences in resistant 
prevalence between the two periods. Further, because 
of the observational design, we were not able to 
attribute the changes in the microbiological patterns 
solely to the implementation of the clinical protocol. 
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And finally, there are many other factors not addressed 
by the protocol such as: antimicrobial prophylaxis 
for neutropenia episodes, local epidemiology, and 
institutional policy for antimicrobial use. These other 
unexplored issues may also play an important role.
CONCLUSION
The microbiological pathogens documented in this 
cohort study are chiefly those expected for neutropenic 
patients who develop a febrile episode. However, the 
emergence of multidrug-resistant P. aeruginosa is of 
serious concern. Data suggests, after the clinical protocol 
for treatment of febrile neutropenia was implemented, 
there was a perceived shift toward prominent Gram-
negative infections. Therefore, continuous surveillance 
is recommended to identify changes in microbiologic 
patterns for the purpose of guiding antimicrobial use. 
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